On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
On February 1, 2016, there was a commercial launch of the generic version of imatinib mesylate (Gleevec) which is approved for CML patients by the FDA. As the first to file for generic marketing [...]
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
A recent study published in the JAMA Internal Medicine reports a link between the use of proton pump inhibitors (PPIs) and an increased risk of kidney disease. More research is warranted to show PPIs [...]
Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. LRG Research Program to [...]
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
Two recent articles summarize the promise that immunotherapy provides for the future of cancer treatment. Immunotherapy refers to treatments that aid your own immune system in fighting cancer cells. The first, from U.S. News and [...]
A recent study in JAMA Oncology found that patients who undergo primary GIST resection might not receive the optimal recommended duration of adjuvant therapy, which can impact their recurrence-free survival(RFS). The study was conducted by [...]
The Life Raft Group is pleased to announce the release of the sixth issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST. [...]
